 |
59 Diseases |  |
17 Trials |
|
17 Trials |  |
538 News |  |
| «12345678 |
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: PETER-PAIN: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (clinicaltrials.gov) - Jul 3, 2018
P1/2, N=16, Recruiting, Sponsor: Boston Medical Center
Not yet recruiting --> Recruiting
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: EMCS-NDPH: Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children (clinicaltrials.gov) - Jun 27, 2018
P1/2, N=150, Not yet recruiting, Sponsor: Boston Children’s Hospital
Not yet recruiting --> Recruiting Initiation date: May 2018 --> Aug 2018
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial primary completion date: LDN-CRPS: Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (clinicaltrials.gov) - Apr 27, 2018
P=N/A, N=40, Recruiting, Sponsor: Stanford University
Initiation date: May 2018 --> Aug 2018 Trial primary completion date: Jun 2017 --> Jun 2019
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Mar 29, 2018
P2, N=60, Not yet recruiting, Sponsor: University of Pennsylvania
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P1/2 trial: EMCS-NDPH: Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children (clinicaltrials.gov) - Feb 27, 2018
P1/2, N=150, Not yet recruiting, Sponsor: Boston Children’s Hospital
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial initiation date, Trial primary completion date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Feb 6, 2018
P2, N=60, Not yet recruiting, Sponsor: VA Office of Research and Development
Trial primary completion date: Jun 2017 --> Jun 2019 Initiation date: Nov 2017 --> Mar 2018 | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date, Trial primary completion date: PETER-PAIN: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (clinicaltrials.gov) - Jan 26, 2018
P1/2, N=16, Not yet recruiting, Sponsor: Boston Medical Center
Initiation date: Nov 2017 --> Mar 2018 | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019 Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jul 2018 --> Feb 2019
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P1/2 trial: PETER-PAIN: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (clinicaltrials.gov) - Sep 12, 2017
P1/2, N=16, Not yet recruiting, Sponsor: Boston Medical Center
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Aug 23, 2017
P2, N=60, Not yet recruiting, Sponsor: VA Office of Research and Development
Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jul 2018 --> Feb 2019 Initiation date: Jul 2017 --> Nov 2017
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - May 30, 2017
P2, N=60, Not yet recruiting, Sponsor: VA Office of Research and Development
Initiation date: Jul 2017 --> Nov 2017 Initiation date: Feb 2017 --> Jul 2017
- | acetylcysteine solution / Generic mfg.
Trial completion, Enrollment change: N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence (clinicaltrials.gov) - Apr 26, 2017
P2, N=111, Completed, Sponsor: VA Office of Research and Development
Initiation date: Feb 2017 --> Jul 2017 Active, not recruiting --> Completed | N=150 --> 111
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial suspension: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=30, Suspended, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | N=150 --> 111 Recruiting --> Suspended
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial initiation date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=30, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Jan 2016
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Jan 4, 2017
P2, N=60, Not yet recruiting, Sponsor: VA Office of Research and Development
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New trial: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Nov 17, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: LDN-in-FM: Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? (clinicaltrials.gov) - Aug 23, 2016
P4, N=140, Recruiting, Sponsor: Rigshospitalet, Denmark
Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Jan 2016 Not yet recruiting --> Recruiting
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P4 trial: LDN-in-FM: Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? (clinicaltrials.gov) - Jun 20, 2016
P4, N=140, Not yet recruiting, Sponsor: Rigshospitalet, Denmark
- acetylcysteine solution / Generic mfg.
Enrollment closed: N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence (clinicaltrials.gov) - Jan 16, 2016
P2, N=150, Active, not recruiting, Sponsor: VA Office of Research and Development
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment change: Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Active, not recruiting N=40 --> 0
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New trial: LDN-CRPS: Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=40, Recruiting, Sponsor: Stanford University
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Jul 2, 2015
P2, N=9, Completed, Sponsor: Massachusetts General Hospital
N=40 --> 0 Active, not recruiting --> Completed | N=36 --> 9
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, HEOR: Low Dose Naltrexone for Glioma Patients (clinicaltrials.gov) - Jun 26, 2015
P2, N=110, Completed, Sponsor: Katy Peters
Active, not recruiting --> Completed | N=36 --> 9 Active, not recruiting --> Completed
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Apr 8, 2015
P2, N=36, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change: BUP/NXT-VIVI: Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (clinicaltrials.gov) - Mar 7, 2015
P2, N=35, Completed, Sponsor: Paolo Mannelli
Recruiting --> Active, not recruiting Recruiting --> Completed | N=20 --> 35
- acetylcysteine solution / Generic mfg.
Trial primary completion date: N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence (clinicaltrials.gov) - Mar 2, 2015
P2, N=150, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=20 --> 35 Trial primary completion date: Dec 2014 --> Sep 2015
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Phase classification, Enrollment change, Trial withdrawal: Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease (clinicaltrials.gov) - Nov 20, 2014
P2, N=0, Withdrawn, Sponsor: Santa Barbara Cottage Hospital
Trial primary completion date: Dec 2014 --> Sep 2015 Phase classification: P4 --> P2 | N=36 --> 0 | Not yet recruiting --> Withdrawn
- Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial primary completion date: BUP/NXT-VIVI: Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (clinicaltrials.gov) - Oct 27, 2014
P2, N=20, Recruiting, Sponsor: Paolo Mannelli
Phase classification: P4 --> P2 | N=36 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Sep 2014 --> Feb 2015
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: LDN-IM: Low Dose Naltrexone (LDN) Immune Monitoring (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=20, Recruiting, Sponsor: Stanford University
Trial primary completion date: Sep 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial termination, Metastases: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer (clinicaltrials.gov) - Mar 10, 2014
P2, N=7, Terminated, Sponsor: Maria Constantinou
Not yet recruiting --> Recruiting Recruiting --> Terminated; Study stopped 10/24/13 secondary to lack of patients/slow enrollment
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment change, Metastases: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer (clinicaltrials.gov) - Mar 10, 2014
P2, N=7, Terminated, Sponsor: Maria Constantinou
Recruiting --> Terminated; Study stopped 10/24/13 secondary to lack of patients/slow enrollment N=13 --> 7
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion: Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=40, Completed, Sponsor: Yale University
N=13 --> 7 No longer recruiting --> Completed
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed, HEOR: Low Dose Naltrexone for Glioma Patients (clinicaltrials.gov) - Jan 14, 2014
P2, N=130, Active, not recruiting, Sponsor: Katy Peters
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment change, HEOR: Low Dose Naltrexone for Glioma Patients (clinicaltrials.gov) - Nov 3, 2013
P2, N=130, Active, not recruiting, Sponsor: Katy Peters
Recruiting --> Active, not recruiting N=72 --> 130
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Sep 26, 2013
P2, N=36, Recruiting, Sponsor: Massachusetts General Hospital
N=72 --> 130 Not yet recruiting --> Recruiting
- naltrexone / Generic mfg.
Trial completion: Naltrexone for Heavy Drinking in Young Adults (clinicaltrials.gov) - Aug 6, 2013
P4, N=140, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Jun 9, 2013
P2, N=36, Recruiting, Sponsor: Massachusetts General Hospital
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P4 trial: Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease (clinicaltrials.gov) - Mar 11, 2013
P4, N=36, Not yet recruiting, Sponsor: Santa Barbara Cottage Hospital
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment change: Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain (clinicaltrials.gov) - Jan 1, 2013
P1/2, N=40, Completed, Sponsor: Yale University
Active, not recruiting --> Completed N=20 --> 40
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date, Metastases: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer (clinicaltrials.gov) - Dec 3, 2012
P2, N=7, Terminated, Sponsor: Maria Constantinou
N=20 --> 40 Initiation date: Aug 2012 --> Nov 2012
- | Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: BUP/NXT-VIVI: Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (clinicaltrials.gov) - Oct 11, 2012
P2, N=20, Recruiting, Sponsor: Paolo Mannelli
Initiation date: Aug 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- | Vivitrol (naltrexone extended-release injectable suspension) / Alkermes, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: BUP/NXT-VIVI: Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (clinicaltrials.gov) - Sep 19, 2012
P2, N=20, Recruiting, Sponsor: Paolo Mannelli
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial, Metastases: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer (clinicaltrials.gov) - Jul 24, 2012
P2, N=7, Terminated, Sponsor: Maria Constantinou
- Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion: Targeted Interventions for Weight-Concerned Smokers (clinicaltrials.gov) - Jan 16, 2012
P2, N=172, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed